首页 | 本学科首页   官方微博 | 高级检索  
     


Single center results of simultaneous pancreas-kidney transplantation in patients with type 2 diabetes
Authors:Phuoc H. Pham  Lily N. Stalter  Eric J. Martinez  Jesse F. Wang  Bridget M. Welch  Glen Leverson  Nicholas Marka  Talal Al-Qaoud  Didier Mandelbrot  Sandesh Parajuli  Hans W. Sollinger  Dixon Kaufman  Robert R. Redfield  Jon S. Odorico
Affiliation:1. Division of Transplantation, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin;2. Division of Transplantation, Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

Anette C. and Harold C. Simmons Transplant Institute, Baylor University Medical Center, Dallas, Texas;3. Division of Nephrology, Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin

Abstract:
Studies have found similar outcomes of Simultaneous Pancreas-Kidney transplantation (SPKT) in patients with Type 2 (T2D) and Type 1 diabetes (T1D). However, there are scarce data evaluating the association of recipient factors such as age, BMI, or pretransplant insulin requirements with outcomes, thus the criteria for the optimal recipient selection remains unclear. In this study, 284 T1D and 39 T2D patients, who underwent SPKT between 2006 and 2017 with 1 year of follow-up at minimum, were assessed for potential relationship of pretransplant BMI and insulin requirements with posttransplant diabetes and pancreatic graft failure. Kaplan-Meier analysis showed similar rates of freedom from posttransplant diabetes (94.7% T2D vs. 92.3% T1D at 1 yr, and 88.1% T2D vs. 81.1% T1D at 5 yrs) and graft survival (89.7% T2D vs. 90.4% T1D at 1 yr, and 89.7% T2D vs. 81.2% T1D at 5 yrs). There was no significant association between BMI or pretransplant insulin requirements with posttransplant diabetes occurrence in either T1D (p = .10, .43, respectively) or T2D (p = .12, .63) patients in the cohort; or with graft failure (T1D: p = .40, .09; T2D: p = .71, .28). These observations suggest a less restricted approach to selective use of SPKT in patients with T2D.
Keywords:clinical decision-making  clinical research/practice  diabetes: new onset/posttransplant  diabetes: type 2  endocrinology/diabetology  health services and outcomes research  immunosuppression/immune modulation  obesity  pancreas/simultaneous pancreas-kidney transplantation  recipient selection
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号